Protagonist Opts Out of Takeda Profit-Sharing Deal for $475 Million in Payments

Key Facts

1Protagonist Therapeutics exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement with Takeda.

2The company is eligible for $200 million upon election and another $200 million upon FDA approval of rusfertide.

3Total potential cash tied to the opt-out and approval reaches $475 million, plus tiered worldwide royalties.

Protagonist Therapeutics has officially exercised its right to opt out of a 50:50 U.S. profit and loss sharing arrangement with Takeda for the drug rusfertide. Under the revised terms, Protagonist is set to receive an immediate payment of $200 million, with an additional $200 million contingent upon FDA approval of the treatment. The total potential cash payments related to this opt-out and subsequent milestones reach $475 million, excluding tiered worldwide royalties. This strategic shift transitions the company from a profit-sharing model to a milestone and royalty-based compensation structure. Analysts view this move as bullish, as it provides a significant non-dilutive cash influx for the mid-cap biotech firm. The agreement effectively de-risks Protagonist's operational profile while validating the commercial potential of its polycythemia vera treatment.